June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 24, 2025

AI vs. MDs: Who Navigates the Airways Better?

A new systematic review evaluated 20 studies on artificial intelligence in bronchoscopy and found AI systems often performed as well as or better than human experts in tasks such as airway navigation and lymph node classification.

Conexiant

June 23, 2025

Remote and Ready: Rethinking COPD Care

A large meta-analysis of 33 trials found that community-based COPD management models improved lung function, exercise capacity, and symptom control compared to usual care, though quality-of-life gains were not significant.

Conexiant

June 18, 2025

Cracking the Code of Phages to Fight TB

How new structural insights captured in high-resolution images could fuel next-gen therapies for TB

The Analytical Scientist

June 17, 2025

FDA-Approved Sweetener Found in Vapes

New laboratory analysis found widespread use of neotame, a potent artificial sweetener, in most disposable e-cigarettes sold in the United States, including nicotine-free and nicotine-analogue products.

Conexiant

June 16, 2025

Neoadjuvant PD-1/PD-L1 Inhibition Plus Chemotherapy in Borderline-Resectable or Unresectable Stage III NSCLC

In a retrospective cohort study reported in JAMA Oncology, Ricciuti et al examined whether neoadjuvant PD-1/PD-L1 inhibition plus platinum-based chemotherapy showed activity in patients with borderlin...

The ASCO Post

June 16, 2025

FDA Approves Therapy for NSCLC With High c-Met Protein Overexpression

The FDA granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis), a c-Met–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, nonsquamous...

The ASCO Post

June 16, 2025

Some Patients With Advanced NSCLC Experience Durable Disease Control After Immunotherapy Discontinuation

A subset of patients with advanced non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitors due to immune-related adverse events continued to experience long-term disease contr...

The ASCO Post

June 16, 2025

AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer

The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation,...

The ASCO Post